北京若生智能科技有限公司
Drug Database
OX

oxybutynin (oxybutynin, TIMERx / Ditropan CR / Cystrin CR)

✓ Approved

Takeda · CHRM1 · 小分子

什么是 oxybutynin？

oxybutynin 是一种小分子，由Takeda研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名oxybutynin, TIMERx, Ditropan CR, Cystrin CR
公司Takeda
药物类别小分子
分子靶点CHRM1, CHRM2, CHRM3, CHRM4
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Takeda

作用机制

分子靶点

oxybutynin 作用于 4 个分子靶点：

CHRM1cholinergic receptor muscarinic 1 (M1, HM1)
CHRM2cholinergic receptor muscarinic 2 (HM2)
CHRM3cholinergic receptor muscarinic 3 (HM3, PBS)
CHRM4cholinergic receptor muscarinic 4 (HM4, M4R)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

oxybutynin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Renal and urinary disordersUrinary incontinence✓ Approved

相关研究文献

PubMedJornal vascular brasileiro2026-10-17

Topical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial).

Neves Samantha S, Crocco Elisete Isabel EI, da Silva Viviane Santana VS, Menegueti Felipe F et al.

Primary hyperhidrosis is a chronic condition with limited therapeutic options. To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.

PMID 42890128
阅读全文 →
PubMedJournal of pediatric urology2026-10-14

An age-matched comparison of early urological outcomes in patients who underwent antenatal versus postnatal myelomeningocele repair: A prospective single centre experience.

Pickett Lianne L, Jayasimha Sudhindra S, Maestri Susan S, Cao Kevin K et al.

Antenatal myelomeningocele (MMC) repair improves neurosurgical outcomes, but its impact on early renal and bladder outcomes remains uncertain. To test the hypothesis that antenatal myelomeningocele repair is associated with fewer symptomatic febrile urinary tract infections during early follow-up than postnatal repair, and to compare secondary upper urinary tract, bladder management and non-invasive bladder function outcomes within a single-centre risk-stratified pathway. We reviewed a prospectively maintained MMC database (2018-2025). All antenatally repaired children were included; postnatal repairs were restricted to children meeting Management of Myelomeningocele Study eligibility criteria. Outcomes included symptomatic febrile UTI, upper urinary tract findings, bladder emptying management, post-void residual urine on non-invasive bladder function assessment, selective uroflowmetry and invasive urodynamics, and symptomatic oxybutynin use. UTI was defined as a febrile episode with UTI-compatible symptoms and urinary leucocytes or pyuria; asymptomatic bacteriuria was not counted. Sixty-six children were managed; Nineteen underwent antenatal repair and 14 formed the MOMS-eligible postnatal comparator group. Prematurity was more frequent after antenatal repair (79% vs 0%, p < 0.001) and ventriculoperitoneal shunt requirement was lower (26% vs 79%, p = 0.005). Symptomatic UTI occurred less often in the antenatal group (21% vs 79%, p = 0.002). Hydronephrosis, VUR, DMSA scarring and overnight drainage all favoured the antenatal group but did not reach statistical significance. Within this small single-centre cohort managed by a consistent risk-stratified pathway, antenatal MMC repair was associated with fewer documented symptomatic febrile UTIs during early follow-up. Differences in upper tract outcomes, bladder emptying management and selectively measured functional outcomes remained uncertain.

PMID 42875283
阅读全文 →
PubMedAnnals of internal medicine2026-10-05

Pharmacologic Treatments for Female Menopausal Vasomotor Symptoms: A Systematic Review and Meta-analysis for the American College of Physicians.

Diem Susan S, Landsteiner Adrienne A, Langsetmo Lisa L, Ullman Kristen K et al.

Vasomotor symptoms (VMS) are common in perimenopausal and postmenopausal females. To evaluate benefits, harms, patient values and preferences, and cost-effectiveness of pharmacologic treatments for VMS. MEDLINE ALL, Embase, and Cochrane Central Register of Controlled Trials from inception to 3 March 2026. Randomized trials of at least 8 weeks' duration of eligible medications in females with VMS reporting VMS frequency and severity, menopause-related quality of life (QoL), sleep quality, endometrial hyperplasia or cancer, and/or serious adverse events (SAEs); U.S. Food and Drug Administration and European Medicines Agency labels for additional harms. Data were abstracted by 1 reviewer and verified by a second reviewer. Independent, dual risk-of-bias assessments were performed. Certainty of evidence (COE) was assessed by 1 reviewer and overread by a second reviewer. Ninety trials were included. COE was low to moderate for most comparisons. Compared with placebo, estrogens with or without progestogens, conjugated estrogen with bazedoxifene (CE/BZA), and oxybutynin reduced VMS frequency and severity. Compared with placebo, neurokinin receptor antagonists (NKRAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), gabapentin, and progestogens reduced VMS frequency but not severity. Estrogen efficacy varied by dose but not route. Estrogens with and without progestogens, CE/BZA, NKRAs, SNRIs, and SSRIs improved menopause-related QoL; gabapentin, NKRAs, oxybutynin, SNRIs, and SSRIs improved sleep quality. Few SAEs were reported. Evidence was insufficient for patient values and preferences. Estrogens with or without progestogens are of high economic value (high COE). The NKRA fezolinetant has low value (moderate COE). Most studies were short-term and were not designed to evaluate SAEs or long-term harms. Observational studies that could address long-term harms were not included. Estrogens reduced VMS frequency and severity and improved QoL (with or without progestogens and with BZA). NKRAs, SNRIs, and SSRIs improved VMS frequency, QoL, and sleep. Estrogens with and without progestogens were of high economic value. Harms data were limited. Little comparative information exists. American College of Physicians. (PROSPERO: CRD42024558116).

PMID 42832800
阅读全文 →
PubMedNeurourology and urodynamics2026-09-21

Sacral Transcutaneous Electrical Nerve Stimulation Versus Oxybutynin in Children With Overactive Bladder: A Prospective Randomized Controlled Trial.

Arunaa Sathyamurthy S, Babu Ramesh R, Madhu Ramasundaram R, Kumaravel Sambandan S

The aim of this RCT is to compare the efficacy of sacral transcutaneous electrical nerve stimulation (TENS) with oxybutynin in children with overactive bladder (OAB), focusing on subjective & objective treatment response, adverse effects, and relapse rates. In this prospective randomized controlled study, 82 children aged 5-18 years with refractory OAB were randomized to receive either sacral TENS (30 sessions; 20 min each (10 Hz) daily; for 4 weeks) or oral oxybutynin (0.2 mg/kg/day for 4 weeks). Outcomes were assessed using subjective response categories based on bladder diaries and objective measures including the Overactive Bladder Index (OABI) and Dysfunctional Voiding Symptom Score (DVSS). Adverse effects and relapse during 6-12 months of follow-up were recorded. There was no significant difference between age/sex distributions between the groups. Median follow-up was 9 (6-12) months. Complete response was significantly higher with TENS than oxybutynin (68.3% vs. 31.7%; OR 4.63, 95% CI 1.8-11.7; p = 0.001). Mean improvement in OABI (4.6 ± 1.4 vs. 3.7 ± 1.0; p = 0.001) and DVSS (8.8 ± 1.5 vs. 5.7 ± 1.3; p = 0.001) favored TENS. Adverse effects (4.9% vs. 46.3%) and relapse rates (7.3% vs. 29.3%) were significantly lower with TENS. Sacral TENS was associated with higher response rates and fewer adverse effects than oxybutynin in this cohort supporting its role as an effective and well-tolerated therapeutic option for pediatric OAB. Further larger trials are warranted.

PMID 42765542
阅读全文 →
PubMedUrologiia (Moscow, Russia : 1999)2026-09-15

[Evaluation of tolerability and cognitive safety of trospium chloride in the treatment of overactive bladder: a systematic review and meta-analysis].

Kuzmin I V V, Slesarevskaya M N N, Al-Shukri S Kh K

Overactive bladder (OAB) is one of the most common lower urinary tract dysfunctions, significantly impairing the quality of life of patients. Pharmacotherapy is the leading treatment for OAB; however, poor tolerability of antimuscarinic drugs prescribed for this condition hinders clinical efficacy in a significant number of patients. To evaluate the tolerability and cognitive safety of the anticholinergic drug trospium chloride (TCh) in the treatment of OAB in adults and children. The study was conducted in accordance with the PRISMA criteria. A search of eLibrary, PubMed, EMBASE, Web of Science, and the Cochrane Library was performed for the period 1991-2025. Randomized and non-randomized controlled trials, as well as prospective observational studies, were included in the analysis. A control group was required in adult studies. A total of 23 studies (15 in adults, 8 in children) were included in the analysis. A total of 2,244 patients (1,934 adults, 310 children) received TCh. Most adverse events (AEs) with TCh were due to the drugs systemic antimuscarinic effect. The most common AEs were dry mouth (OR 3.75; 95% CI 2.83-4.97; NNH = 6.0) and constipation (OR 2.69; 95% CI 1.72-4.19; NNH = 17.1). The incidence of peripheral AEs with TCh is comparable to that with other antimuscarinic agents used to treat OAB, with the exception of oxybutynin, which is significantly less well-tolerated. Unlike other anticholinergic drugs, TCh does not affect the central nervous system or cause cognitive impairment. TCh was well tolerated in children at age-appropriate doses. The results of the study demonstrate good tolerability of TCh in adults and children. A significant advantage of TCh is its cognitive safety. Along with its clinical efficacy, this allows TCh to be considered as a first-line anticholinergic therapy in adults with OAB, particularly in elderly patients and those at high risk of cognitive impairment. Further studies of the long-term safety of TCh in patients of different age groups are warranted.

PMID 42742564
阅读全文 →
PubMedThe journal of spinal cord medicine2026-08-20

Off-target effects of percutaneous epidural spinal cord and dorsal root ganglion stimulation with task-specific training on lower urinary tract function in individuals with chronic spinal cord injury.

Soong Christina C, Veith Daniel D DD, Gill Megan L ML, Beck Lisa A LA et al.

This study aimed to evaluate the off-target effects of motor-optimized SCS-enabled task-specific training (SCS-TST) on lower urinary tract function through self-reported data from individuals with chronic spinal cord injury (SCI), using the Neurogenic Bladder Symptom Score (NBSS). A secondary objective was to explore whether participant characteristics or bladder treatments were associated with changes in NBSS outcomes. Datasets from two prospective pilot trials using percutaneous spinal cord stimulation (SCS) to enable motor function were analyzed and reported. Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, Minnesota. Adults ≥ 1-year post traumatic SCI. Participants received either 12 days of epidural stimulation (ES) or 10 days of ES and dorsal root ganglion stimulation (ESDRS), each coupled with 6-8 SCS-TST sessions. NBSS was administered pre- and post-intervention. Analysis of 23 participants (ES, n = 3; ESDRS, n = 20) showed no significant group-level changes in total NBSS (p = 0.49) or functional domains (p = 0.56-0.85). Individually, 83% demonstrated no clinically meaningful change, while 9% improved and 9% worsened. Exploratory analyses identified that symptom change was associated with neurological level of injury (p = 0.017), age (p = 0.026), and marginally associated with injury severity (p = 0.055). Oxybutynin use was associated with lower symptom variability, without statistical significance (p = 0.074). Motor-optimized SCS-TST did not lead to significant group-level changes in patient-reported urinary symptoms. However, a subset of individuals experienced improvement or worsening, suggesting that injury characteristics and medication use may influence urinary outcomes. These preliminary findings warrant confirmation in larger, adequately powered trials.Trial Registration: ClinicalTrials.gov identifiers: NCT05095454, NCT04736849.

PMID 42622482
阅读全文 →

注册免费账户还可查看另外 1608 篇文献

免费注册查看全部文献 →

了解更多oxybutynin